Whether providing seed funding to startups, growth capital to early-stage companies, or financing buyouts, venture capital funding plays a critical role in sustaining the life sciences ecosystem.
Our global team of venture capital lawyers advise venture capital funds, life sciences companies with a captive venture fund, as well as universities and other academic research institutions. We provide multidisciplinary advice throughout the "venture capital lifecycle from company formation through fundraising and investments to eventual exit.
Regulation is simply a reality of doing business in this industry. Our venture capital lawyers regularly access our world-renowned global regulatory team to perform due diligence investigations of regulatory issues and risk factors, including the relevant approval pathway and reimbursement strategy for your product. We also serve as special regulatory counsel to issuers and underwriters in conjunction with initial public offerings and follow-on offerings.
Many of our team members have in-depth experience in industry and government, including at the FDA and other key regulatory agencies, and hold advance degrees in relevant disciplines.
Centogene on its €25m Series A financing.
Gilead Sciences on its investment on the US$120m Series B financing of AlloVir, formerly known as ViraCyte.
Gilead subsidiary, Kite Pharma, on its investment in HifiBio's US$67m Series C financing.
New Enterprise Associates on multiple equity investments, including its Series A investment in Vtesse and Series C investments in NightStarX and Mirum Pharmaceuticals.
Novartis Institutes for Biomedical Research on a number of venture capital transactions.
